AbbVie/ Merck Inc/ Novartis/ R&D/ US/ Views and analysis 2016 saw slump in FDA drug approvals, but 2017 could be return to form Andrew McConaghie FDA approvals, R&D productivity 0 Comment FDA approvals could rebound in 2017 – but concerns about big pharma R&D productivity won’t go away. Share X 2016 saw slump in FDA drug approvals, but 2017 could be return to form https://pharmaphorum.com/views-and-analysis/2016-saw-slump-fda-drug-approvals-2017-return-form/
Articles/ Cancer/ Clinical/ Pharma Market Access/ R&D/ Sales and Marketing/ US/ Views and analysis After 2015’s ‘breakthrough’ year for pharma approvals, will 2016 see a dip? Andrew McConaghie Alzheimer's, FDA approvals, Hep B, Hep C, Hepatitis, market access, MS, pharma 0 Comment Roche’s MS drug is among major drugs still to come in 2016. Share X After 2015’s ‘breakthrough’ year for pharma approvals, will 2016 see a dip? https://pharmaphorum.com/views-and-analysis/2015-breakthrough-year-pharma-approvals-will-2016-see-dip/
Articles/ Views and analysis 10 drugs – and their prices – which changed pharma in 2015 Andrew McConaghie Entresto, FDA approvals, ICER, Opdivo, Orkambi 0 Comment In a record-breaking year for pharma, which drugs were the most outstanding? Share X 10 drugs – and their prices – which changed pharma in 2015 https://pharmaphorum.com/views-and-analysis/10-drugs-and-their-prices-which-changed-pharma-in-2015/